Screening for a sometimes fatal condition among patients with a rare autoimmune disease could soon - thanks to a computer algorithm - become even more accurate. Researchers at Michigan Medicine found ...

Expert Rev Resp Med. 2009;3(2):187-196. Paul M. Hassoun, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21224, ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Please provide your email address to receive an email when new articles are posted on . Interstitial lung disease and pulmonary arterial hypertension associated with scleroderma often require ...

Screening for a sometimes fatal condition among patients with a rare autoimmune disease could soon - thanks to a computer algorithm - become even more accurate. Researchers at Michigan Medicine found ...

The agency has approved nintedanib (Ofev) to slow the rate of pulmonary function decline in adult patients with interstitial lung disease associated with systemic sclerosis or scleroderma. The FDA has ...

CHICAGO -- Rheumatologists need to be alert for pulmonary hypertension (PH) in their patients and have some understanding of its proper management, a researcher said here, because the condition is ...

The Food and Drug Administration (FDA) has approved Ofev (nintedanib; Boehringer Ingelheim) capsules as the first FDA-approved treatment to slow the rate of decline in pulmonary function in patients ...

PHILADELPHIA (WPVI) -- When a rare disease strikes, getting a diagnosis can take years, enabling the disease to progress. A young woman from the Mayfair section of Philadelphia details her battle to ...

Patients who underwent autologous stem cell transplantation (ASCT) for diffuse cutaneous systemic sclerosis (dcSSc), also known as scleroderma, did no better than others receiving conventional ...

Scleroderma-related PAH remains a syndrome that is difficult to treat with currently available medical therapy, for reasons that are poorly understood. Although classified within the group 1 (PAH) of ...